Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

This article, presented in the backdrop of the debates on the state of political theory in India, argues that the terms of ...

Introduction Application of artificial intelligence (AI) tools in the healthcare setting gains importance especially in the domain of disease diagnosis. Numerous studies have tried to explore AI in ...

Want to write a novel in 2026? Or maybe 13 novels? Here's how one incredibly prolific writer gets it all done.

After completing your single task (and taking a break to acknowledge your progress), you move to the next concrete action.

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

The strategic insertion of the past is no longer incidental in Bollywood films. It has become a deliberate trope in ...

Popular AI-powered integrated development environment solutions, such as Cursor, Windsurf, Google Antigravity, and Trae, ...